SCHEMBL5724067

SCHEMBL5724067

CC(=O)SC1CN(c2nc(CN3C(=O)c4ccccc4C3=O)cs2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.41
HPGD P15428 2/20 0.41
PKM P14618 2/20 0.40
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 2/20 0.39
RECQL P46063 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 3/20 0.38
DNM1L O00429 6/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TP53 P04637 1/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724161 0.84 DNM1L (0.36) DNM1L
SCHEMBL5724068 0.83 LMNA (0.43) POLBHPGDPKMLMNASMN1; SMN2
SCHEMBL5724251 0.77 PKM (0.40) POLBHPGDPKMLMNASMN1; SMN2
SCHEMBL5723668 0.74 KDM4E (0.48) HPGDPKMLMNASMN1; SMN2MAPT
SCHEMBL5724179 0.73 LMNA (0.38) POLBHPGDPKMLMNASMN1; SMN2
SCHEMBL5723956 0.72 HRH3 (0.33) DNM1L
SCHEMBL5826389 0.71 RAB9A (0.34) PKMLMNASMN1; SMN2NPC1RAB9A
SCHEMBL19762475 0.70 PKM (0.74) POLBHPGDPKMLMNASMN1; SMN2
SCHEMBL5724368 0.69 PARP1 (0.33) SMN1; SMN2CYP1A2CYP2D6CYP2C9RAB9A
SCHEMBL5724215 0.68 OGA (0.42) POLBHPGDL3MBTL1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD POLB 1328/4885HPGD 1268/4885PKM 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.